Baseline characteristics of the participants according to baseline hematocrit levels and sex
| Characteristics . | Male . | Female . | ||||
|---|---|---|---|---|---|---|
| Anemia∗ . | Normal . | Erythrocytosis† . | Anemia∗ . | Normal . | Erythrocytosis† . | |
| N = 1656 . | N = 7095 . | N = 524 . | N = 742 . | N = 4215 . | N = 89 . | |
| Age, y | 64 (57-69) | 63 (56-68) | 60 (53-66) | 62 (56-68) | 64 (56-68) | 60 (56-66) |
| Race, n (%) | ||||||
| White | 1085 (66) | 5431 (77) | 401 (77) | 436 (59) | 3271 (78) | 69 (78) |
| Black or African American | 72 (4) | 193 (3) | 17 (3) | 70 (9) | 196 (5) | 3 (3) |
| Asian | 392 (24) | 1059 (15) | 50 (10) | 188 (25) | 446 (11) | 1 (1) |
| Other‡ | 107 (6) | 412 (6) | 56 (11) | 48 (6) | 302 (7) | 16 (18) |
| Current smoker, n (%) | 213 (13) | 1351 (19) | 160 (31) | 45 (6) | 605 (14) | 27 (30) |
| History of hypertension, n (%) | 1539 (93) | 6452 (91) | 477 (91) | 693 (93) | 3945 (94) | 84 (94) |
| History of CV disease, n (%) | 1028 (62) | 4645 (65) | 341 (65) | 375 (51) | 2276 (54) | 49 (55) |
| History of MI, n (%) | 332 (20) | 1988 (28) | 149 (28) | 99 (13) | 743 (18) | 20 (22) |
| History of cerebrovascular, n (%) | 281 (17) | 1223 (17) | 98 (19) | 129 (17) | 864 (20) | 14 (16) |
| Diabetes duration, y | 15.3 (10.0-21.0) | 13.0 (8.0-18.0) | 11.0 (6.0-16.0) | 15.2 (11.0-21.0) | 13.0 (9.0-19.0) | 11.3 (7.0-17.0) |
| Body mass index, kg/m2 | 30 (26-34) | 31 (28-35) | 31 (28-35) | 30 (27-36) | 32 (28-36) | 32 (29-36) |
| SBP, mm Hg | 139 (128-150) | 137 (127-147) | 137 (128-145) | 139 (128-150) | 138 (128-148) | 135 (130-145) |
| DBP, mm Hg | 76 (69-82) | 79 (72-85) | 81 (77-87) | 76 (68-82) | 79 (71-84) | 80 (76-86) |
| Glycated hemoglobin, % | 7.9 (7.3-8.7) | 8.1 (7.4-8.9) | 8.2 (7.5-9.1) | 8.0 (7.4-9.0) | 8.2 (7.6-9.1) | 8.3 (7.6-9.4) |
| eGFR, mL/min per 1.73 m2 | 57 (42-73) | 73 (59-87) | 73 (58-87) | 53 (41-69) | 71 (56-86) | 72 (60-92) |
| UACR, mg/g | 402 (25-1277) | 27 (8-392) | 119 (12-718) | 440 (20-1506) | 17 (8-312) | 37 (9-562) |
| Hemoglobin, g/dL | 121 (113-127) | 144 (137-152) | 166 (161-172) | 110 (104-114) | 132 (125-140) | 159 (153-165) |
| Hematocrit, % | 36 (35-38) | 43 (41-45) | 51 (50-53) | 34 (32-35) | 40 (38-43) | 50 (49-51) |
| WBC count, 109/L | 6.86 (5.71-8.14) | 7.11 (6.05-8.40) | 7.42 (6.32-8.88) | 6.84 (5.77-8.11) | 7.17 (6.04-8.51) | 7.55 (6.39-8.99) |
| Platelet count, 109/L | 232 (194-279) | 226 (190-269) | 215 (181-253) | 273 (220-329) | 258 (217-305) | 223 (194-287) |
| Total cholesterol, mmol/L | 3.95 (3.36-4.71) | 4.07 (3.49-4.86) | 4.48 (3.65-5.40) | 4.46 (3.76-5.23) | 4.68 (3.93-5.59) | 4.82 (4.27-5.59) |
| HDL cholesterol, mmol/L | 1.04 (0.88-1.26) | 1.06 (0.92-1.26) | 1.04 (0.89-1.22) | 1.19 (1.01-1.42) | 1.25 (1.07-1.48) | 1.26 (1.09-1.44) |
| LDL cholesterol, mmol/L | 1.97 (1.51-2.59) | 2.07 (1.58-2.73) | 2.37 (1.73-3.11) | 2.29 (1.73-3.02) | 2.46 (1.83-3.23) | 2.53 (2.02-3.28) |
| Triglycerides, mmol/L | 1.63 (1.14-2.37) | 1.71 (1.22-2.47) | 1.92 (1.37-2.76) | 1.70 (1.25-2.34) | 1.76 (1.32-2.44) | 1.89 (1.35-2.75) |
| Medication, n (%) | ||||||
| ACE inhibitors/ARB | 1490 (90) | 6039 (85) | 452 (86) | 688 (93) | 3601 (85) | 77 (87) |
| Diuretics | 852 (51) | 2976 (42) | 208 (40) | 392 (53) | 1985 (47) | 40 (45) |
| β blocker | 783 (47) | 3678 (52) | 242 (46) | 278 (37) | 2047 (49) | 50 (56) |
| Statin | 1291 (78) | 5431 (77) | 340 (65) | 514 (69) | 2837 (67) | 63 (71) |
| Antithrombotic agents§ | 1173 (71) | 5282 (74) | 377 (72) | 437 (59) | 2607 (62) | 61 (69) |
| Insulin | 1025 (62) | 3762 (53) | 267 (51) | 503 (68) | 2278 (54) | 44 (49) |
| Characteristics . | Male . | Female . | ||||
|---|---|---|---|---|---|---|
| Anemia∗ . | Normal . | Erythrocytosis† . | Anemia∗ . | Normal . | Erythrocytosis† . | |
| N = 1656 . | N = 7095 . | N = 524 . | N = 742 . | N = 4215 . | N = 89 . | |
| Age, y | 64 (57-69) | 63 (56-68) | 60 (53-66) | 62 (56-68) | 64 (56-68) | 60 (56-66) |
| Race, n (%) | ||||||
| White | 1085 (66) | 5431 (77) | 401 (77) | 436 (59) | 3271 (78) | 69 (78) |
| Black or African American | 72 (4) | 193 (3) | 17 (3) | 70 (9) | 196 (5) | 3 (3) |
| Asian | 392 (24) | 1059 (15) | 50 (10) | 188 (25) | 446 (11) | 1 (1) |
| Other‡ | 107 (6) | 412 (6) | 56 (11) | 48 (6) | 302 (7) | 16 (18) |
| Current smoker, n (%) | 213 (13) | 1351 (19) | 160 (31) | 45 (6) | 605 (14) | 27 (30) |
| History of hypertension, n (%) | 1539 (93) | 6452 (91) | 477 (91) | 693 (93) | 3945 (94) | 84 (94) |
| History of CV disease, n (%) | 1028 (62) | 4645 (65) | 341 (65) | 375 (51) | 2276 (54) | 49 (55) |
| History of MI, n (%) | 332 (20) | 1988 (28) | 149 (28) | 99 (13) | 743 (18) | 20 (22) |
| History of cerebrovascular, n (%) | 281 (17) | 1223 (17) | 98 (19) | 129 (17) | 864 (20) | 14 (16) |
| Diabetes duration, y | 15.3 (10.0-21.0) | 13.0 (8.0-18.0) | 11.0 (6.0-16.0) | 15.2 (11.0-21.0) | 13.0 (9.0-19.0) | 11.3 (7.0-17.0) |
| Body mass index, kg/m2 | 30 (26-34) | 31 (28-35) | 31 (28-35) | 30 (27-36) | 32 (28-36) | 32 (29-36) |
| SBP, mm Hg | 139 (128-150) | 137 (127-147) | 137 (128-145) | 139 (128-150) | 138 (128-148) | 135 (130-145) |
| DBP, mm Hg | 76 (69-82) | 79 (72-85) | 81 (77-87) | 76 (68-82) | 79 (71-84) | 80 (76-86) |
| Glycated hemoglobin, % | 7.9 (7.3-8.7) | 8.1 (7.4-8.9) | 8.2 (7.5-9.1) | 8.0 (7.4-9.0) | 8.2 (7.6-9.1) | 8.3 (7.6-9.4) |
| eGFR, mL/min per 1.73 m2 | 57 (42-73) | 73 (59-87) | 73 (58-87) | 53 (41-69) | 71 (56-86) | 72 (60-92) |
| UACR, mg/g | 402 (25-1277) | 27 (8-392) | 119 (12-718) | 440 (20-1506) | 17 (8-312) | 37 (9-562) |
| Hemoglobin, g/dL | 121 (113-127) | 144 (137-152) | 166 (161-172) | 110 (104-114) | 132 (125-140) | 159 (153-165) |
| Hematocrit, % | 36 (35-38) | 43 (41-45) | 51 (50-53) | 34 (32-35) | 40 (38-43) | 50 (49-51) |
| WBC count, 109/L | 6.86 (5.71-8.14) | 7.11 (6.05-8.40) | 7.42 (6.32-8.88) | 6.84 (5.77-8.11) | 7.17 (6.04-8.51) | 7.55 (6.39-8.99) |
| Platelet count, 109/L | 232 (194-279) | 226 (190-269) | 215 (181-253) | 273 (220-329) | 258 (217-305) | 223 (194-287) |
| Total cholesterol, mmol/L | 3.95 (3.36-4.71) | 4.07 (3.49-4.86) | 4.48 (3.65-5.40) | 4.46 (3.76-5.23) | 4.68 (3.93-5.59) | 4.82 (4.27-5.59) |
| HDL cholesterol, mmol/L | 1.04 (0.88-1.26) | 1.06 (0.92-1.26) | 1.04 (0.89-1.22) | 1.19 (1.01-1.42) | 1.25 (1.07-1.48) | 1.26 (1.09-1.44) |
| LDL cholesterol, mmol/L | 1.97 (1.51-2.59) | 2.07 (1.58-2.73) | 2.37 (1.73-3.11) | 2.29 (1.73-3.02) | 2.46 (1.83-3.23) | 2.53 (2.02-3.28) |
| Triglycerides, mmol/L | 1.63 (1.14-2.37) | 1.71 (1.22-2.47) | 1.92 (1.37-2.76) | 1.70 (1.25-2.34) | 1.76 (1.32-2.44) | 1.89 (1.35-2.75) |
| Medication, n (%) | ||||||
| ACE inhibitors/ARB | 1490 (90) | 6039 (85) | 452 (86) | 688 (93) | 3601 (85) | 77 (87) |
| Diuretics | 852 (51) | 2976 (42) | 208 (40) | 392 (53) | 1985 (47) | 40 (45) |
| β blocker | 783 (47) | 3678 (52) | 242 (46) | 278 (37) | 2047 (49) | 50 (56) |
| Statin | 1291 (78) | 5431 (77) | 340 (65) | 514 (69) | 2837 (67) | 63 (71) |
| Antithrombotic agents§ | 1173 (71) | 5282 (74) | 377 (72) | 437 (59) | 2607 (62) | 61 (69) |
| Insulin | 1025 (62) | 3762 (53) | 267 (51) | 503 (68) | 2278 (54) | 44 (49) |
Hematocrit values at baseline were available for 98.5% of the total cohort (14 321/14 543), 98.5% of males (9275/9416), and 98.4% of females (5046/5127). Unless otherwise indicated, values are presented as the median (25th-75th percentile).
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; UACR, urine albumin-creatinine ratio; WBC, white blood cell.
Anemia was defined as a hematocrit level of <39% in males or <36% in females.
Erythrocytosis was defined as a hematocrit level of >49% in males or >48% in female.
Other include American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple, other, unknown, and not reported.
Antithrombotic agents include antiplatelets and anticoagulants.